Kadcyla is an oncology drug used to treat certain types of breast cancer. It is a targeted therapy that works by blocking the HER2 protein, which is found in some types of breast cancer cells. Kadcyla is administered intravenously and is used in combination with other treatments such as chemotherapy and radiation. It is approved for use in the United States, Europe, and other countries. Kadcyla is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, such as ovarian and lung cancer. The drug is also being studied for its potential to reduce the risk of recurrence in patients who have already been treated for breast cancer. The Kadcyla market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as Roche, Novartis, and Pfizer are all involved in the development and marketing of Kadcyla. Other companies such as Merck, AstraZeneca, and Eli Lilly are also involved in the development and marketing of the drug. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
